Reslizumab subcutaneous (SC) vs placebo
Clinically significant adverse events leading to discontinuation · people with asthma
Reslizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (moderate certainty).
1 finding from 1 review
- Risk ratio 4.87 [0.57, 41.4]1 study · 464 participantsModerate